ARTICLE | Clinical News

Ziopharm preclinical data

April 23, 2012 7:00 AM UTC

In mouse xenograft models of breast cancer, Zymafos in combination with the regulated in vivo expression of IL-12 significantly inhibited tumor growth by about 71-90% vs. either Zymafos or IL-12 alone (p<0.001 for both). Zymafos plus IL-12 also increased median survival by 8-14 days vs. either product alone. Mice received Zymafos in combination with Ad-RTS-mIL-12, an adenoviral vector expressing murine IL-12 under the control of the RheoSwitch Therapeutic System (RTS) from Intrexon Corp. (Blacksburg, Va.). RTS is an inducible promoter system regulated by the oral small molecule activator ligand INXN-1001. Data were presented at the American Association for Cancer Research meeting in Chicago. ...